Novartis CEO: Hopeful to Accelerate Growth in Second Half

The transcript discusses the impact of COVID-19 on Novartis and the healthcare system, highlighting the company's focus on ophthalmology, dermatology, and new launches. It covers the development of a COVID treatment with Molecular Partners and the challenges of vaccine rollout. The conversation also touches on the future management of COVID-19, including potential virus evolution and the need for ongoing vaccinations. Finally, it addresses Novartis' engagement with the new US administration and its commitment to expanding patient access and affordability.

How does the speaker describe the current state of healthcare systems in relation to the pandemic?

What are the therapeutic areas that Novartis is focusing on as healthcare systems return to normal?

What are the expected outcomes of the vaccination rollouts mentioned in the text?

What novel technology is being used in the COVID treatment being developed by Novartis?

What challenges does the speaker mention regarding the vaccine rollout in different parts of the world?

How does the speaker compare the development of the COVID-19 vaccine to past vaccine developments?

What is the speaker's perspective on the future of COVID-19 as a public health issue?